Publications

 


  • 326. Gleason score, age and screening: Modeling dedifferentiation in prostate cancer

    Draisma G, Postma R, schröder FH, van der Kwast TH, de Koning HJ, 2006

    Journal: Int J Cancer
    Reference: 119, 2366–2371

    paper

  • 325. Screening for prostate cancer in Dutch hereditary prostate cancer families

    Kiemeny LA, Broeders MJ, Pelger M, Kil PJ, Schröder FH, Witjes JA, vasen HF, 2008

    Journal: Int. J cancer
    Reference: 122, 871–876

    paper

  • 324. Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels <3.0 ng/ml? A Comparison of Biopsy Results of PCPT and Outcome-Related Information from ERSPC

    Schröder FH, Bangma CH, Roobol MJ, 2008

    Journal: Eur Urol
    Reference: 53(5):901-908

    paper

  • 323. The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer

    Gosselaar C, Roobol MJ, Roemeling S, Wolters T, van Leenders GJLH, Schröder FH, 2008

    Journal: BJUI Int
    Reference: 101;685 – 690

    paper

  • 322. Sensitivity in cancer screening

    Hakama M, Auvinen A, Day NE, Miller AB, 2007

    Journal: J Med screening
    Reference: 14:174-177

    paper

  • 319. Re: Is a screening interval of every 4 years for prostate cancer acceptable?

    Roobol MJ, Schröder FH, 2008

    Journal: JNCI
    Reference: 100(3):222

    paper

  • 318. Early versus delayed endocrine therapy for prostate cancer

    Schröder FH, 2007

    Journal: Endocrine rel cancer
    Reference: 14:1-11

    paper

  • 317. Should we replace the Gleason score with the amount of high-grade prostate cancer?

    Vis AN, Roemeling S, Kranse R, Schröder FH, Kwast T.H, 2007

    Journal: Eur Urol
    Reference: 51:931-939

    paper

  • 316. KLF6 IVS1 -27G>A variant and the risk of prostate cancer in Finland.

    Seppälä EH, Autio V, Duggal P, Ikonen T, Stenman UH, Auvinen A, Bailey-Wilson JE, Tammela TL, Schleutker J, 2007

    Journal: Eur Urol
    Reference: Oct;52(4):1076-81

    paper

  • 315. Assessment of causes of death in a prostate cancer screening trial.

    Mäkinen T, Karhunen P, Aro J, Lahtela J, Määttänen L, Auvinen A., 2008

    Journal: Int. J cancer
    Reference: Oct 12;122(2):413-417

    paper

  • 314. Diagnostic Value of Free Prostate-Specific Antigen among Men with a Prostate-Specific Antigen Level of <3.0mug per Liter.

    Finne P, Auvinen A, Määttänen L, Tammela TL, Ruutu M, Juusela H, Martikainen P, Hakama M, Stenman UH., 2008

    Journal: Eur Urol
    Reference: 54(2):362-70

    paper

  • 313. Early Detection of Prostate Cancer in 2007 Part 1: PSA and PSA Kinetics.

    Schröder FH, Carter HB, Wolters T, van den Bergh RC, Gosselaar C, Bangma CH, Roobol MJ, 2008

    Journal: Eur Urol
    Reference: 53:468-477

    paper

  • 312. Can non-malignant biopsy features identify men at increased risk of biopsy-detectable prostate cancer at re-screening after 4 years?

    Wolters T, Roobol MJ, Schröder FH, van der Kwast TH, Roemeling S, van der Cruijsen-Koeter IW, Bangma CH, van Leenders GJ, 2008

    Journal: BJUI Int
    Reference: 101(3):283-288

    paper

  • 311. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations.

    Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schröder FH, 2007

    Journal: Cancer
    Reference: Nov 15;110(10):2218-21

    paper

  • 310. Editorial: Is a Screening Interval of Every 4 Years for Prostate Cancer Acceptable?

    Crawford ED, 2007

    Journal: JNCI
    Reference: Sep5:99(17):304

    paper

  • 309. Interval Cancers in Prostate Cancer Screening: Comparing 2- and 4-Year Screening Intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam

    Roobol MJ, Grenabo A, Schröder FH, Hugosson J, 2007

    Journal: JNCI
    Reference: Sep 5;99(17):1296-303

    paper

  • 308. Commentary on: How common is PSA screening in elderly men with limited life expectancies?

    Bangma CH, Roobol MJ, 2007

    Journal: Nat Clin Prac
    Reference: Oct;4(10):532-3

    paper

  • 307. Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA) – Results from a prospective, population-based,randomised study

    Carlsson S, aus G, Wessman C, Hugosson J, 2007

    Journal: Eur Urol
    Reference: Sep;43(14):2109-16

    paper

  • 306. Overall Survival in the Intervention Arm of a Randomized Controlled Screening Trial for Prostate Cancer Compared with a Clinically Diagnosed Cohort

    Vis AN, Roemeling S, Reedijk AJM, Otto SJ, Schröder FH, 2008

    Journal: Eur Urol
    Reference: 53(1):91-98

    paper

  • 305. Words of Wisdom: Re: Prostate-Specific Antigen (PSA) and PSA Velocity for Prostate Cancer Detection in Men Aged <50 Years

    Schröder FH, Roobol MJ, 2007

    Journal: Eur Urol
    Reference: 67:21:00

    paper

  • 304. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

    Khatami A, Aus G, Damber J-E, Lilja H, Lodding P, Hugosson J, 2006

    Journal: Int. J cancer
    Reference: 120: 170-174

    paper

  • 303. Prospective Validation of Active Surveillance in Prostate Cancer: The PRIAS Study

    van den Bergh RCN, Roemeling S, Roobol MJ, Roobol W, Schröder FH, Bangma CH, 2007

    Journal: Eur Urol
    Reference: Dec;52(6):1560-3.

    paper

  • 302. Words of Wisdom: Re: Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer

    Schröder FH, 2007

    Journal: Eur Urol
    Reference: May 51-5: 1443-1444

    paper

  • 301. Words of Wisdom Re: Longitudinal PSA Changes in Men with and without Prostate Cancer: Assessment of Prostate Cancer Risk

    Roobol MJ, 2007

    Journal: Eur Urol
    Reference: May 51-5: 1441-1442

    paper

  • 300. Words of wisdom: Re: Long-term Prediction of Prostate Cancer up to 25 Years before Diagnosis of Prostate Cancer Using Prostate Kallikreins Measured at Age 44 to 50 Years

    Bangma CH, 2007

    Journal: Eur Urol
    Reference: May 51- 5:1439-1440

    paper

  • 299. Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial.

    Roemeling S, Roobol MJ, Otto SJ, Habbema DF, Gosselaar C, Lous JJ, Cuzick J, Schroder FH., 2007

    Journal: Prostate
    Reference: Jul 1;67(10):1053-60.

    paper

  • 298. hK2 and Free PSA, a Prognostic Combination in predicting Minimal Prostate Cancer in screen-Detected Men within the PSA Range 4-10 ng/ml.

    Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH., 2007

    Journal: Eur Urol
    Reference: 07-04-20

    paper

  • 297. Overdiagnosis and overtreatment of early detected prostate cancer

    Bangma CH, Roemeling S, Schröder FH, 2007

    Journal: World J Urol
    Reference: Mar;25(1):3-9.

    paper

  • 296. Cancer Detection and Cancer Characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC) – Section Rotterdam A Comparison of Two Rounds of Screening

    Postma R, Schröder FH, van Leenders GJLH, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast Th H, 2007

    Journal: Eur Urol
    Reference: 07-01-16

    paper

  • 295. Do we need the final results of the ERSPC trial?

    Albers P, 2007

    Journal: Eur Urol
    Reference: 51:291-292

    paper

  • 294. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.

    Stephan C, Meyer HA, Kwiatkowski M, Recker F, Cammann H, Loening SA, Jung K, Lein M., 2006

    Journal: Eur Urol
    Reference: Nov;50(5):1014-20

    paper

  • 293. Seasonality of Serum Prostate-Specific Antigen levels, A Population-Based Study.

    Salama G, Noirot O, Bataille V, Malavaud S, Rebillard X, Villers A, Malavaud B; for the French arm of the ERSPC study., 2007

    Journal: Eur Urol
    Reference: Sep;52(3):708-14

    paper

  • 292. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.

    Maattanen L, Hakama M, Tammela TL, Ruutu M, Ala-Opas M, Juusela H, Martikainen P, Stenman UH, Auvinen A., 2007

    Journal: Br J Cancer
    Reference: Jan 15;96(1):56-60

    paper

  • 291. Active Surveillance for Prostate Cancers Detected in Three Subsequent Rounds of a Screening Trial: Characteristics, PSA Doubling Times, and Outcome.

    Roemeling S, Roobol MJ, de Vries SH, Wolters T, Gosselaar C, van Leenders GJ, Schroder FH., 2007

    Journal: Eur Urol
    Reference: May;51(5):1244-50; discussion 1251

    paper

  • 290. Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy controls?

    Korfage IJ, de Koning HJ, Habbema JD, Schroder FH, Essink-Bot ML., 2007

    Journal: BJUI
    Reference: Apr;99(4):801-6.

    paper

  • 288. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).

    Roobol MJ, Zappa M, Maattanen L, Ciatto S., 2007

    Journal: Prostate
    Reference: Mar 1;67(4):439-46.

    paper

  • 287. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.

    Steyerberg EW, Roobol MJ, Kattan MW, van der Kwast TH, de Koning HJ, Schroder FH., 2007

    Journal: J Urol
    Reference: Jan;177(1):107-12; discussion 112.

    paper

  • 286. Metastatic disease of screen-detected prostate cancer: characteristics at diagnosis

    Roemeling S, Kranse R, Vis AN, Gosselaar C, van der Kwast TH, Schröder FH, 2006

    Journal: Cancer
    Reference: 107(12):2779-85

    paper

  • 285. The case for prostate cancer screening with PSA

    Andriole G, Djavan B, Fleshner N, Schröder FH, 2006

    Journal: Eur Urol supp.
    Reference: supplement 5:737-745

    paper

  • 284. Biomarkers and screening for prostate cancer

    Schröder FH, 2006

    Journal: Ann of Oncology
    Reference: 17: supp. 10

    paper

  • 283. Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized Controlled Trial

    Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J, 2007

    Journal: Eur Urol
    Reference: 2007 Mar;51(3):659-64

    paper

  • 282. Screening for Prostate Cancer at Low PSA Range: The Impact of Digital Rectal Examination on Tumor Incidence and Tumor Characteristics

    Gosselaar C, Roobol MJ, Roemeling S, van der Kwast TH, Schröder FH, 2007

    Journal: Prostate
    Reference: 67(2):154-61.

    paper

  • 281. Tumor characteristics and prognostic factors in two subsequent screening rounds with 4-year interval within prostate cancer screening trial, ERSPC Rotterdam

    van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast T.H, Kirkels WJ, Schröder F.H., 2006

    Journal: Urology
    Reference: 68:615-620

    paper

  • 280. Prostate Cancer in the Swedish Section of ERSPC—Evidence for Less Metastases at Diagnosis but not for Mortality Reduction

    Schröder FH, Habbema JDF, Roobol MJ, Bangma CH, 2006

    Journal: Eur Urol
    Reference: 14-07-28

    paper

  • 279. Bepaling van het individuele risico op prostaatkanker en indolente tumoren

    Bangma CH, Roobol MJ, Schröder FH., 2006

    Journal: NTvU
    Reference: 5:148-151

    paper

  • 278. Establishing normal reference ranges for PSA change with age in a population based study: The Krimpen study

    Bosch JLHR, Tilling K,Bohnen AM, Donovan JL, 2006

    Journal: Prostate
    Reference: 66; 335-343

    paper

  • 277. Risk of cardiovascular mortality in prostate cancer patients in the Rotterdam randomized screening trial

    Otto SJ, Schröder FH, De Koning HJ, 2006

    Journal: JCO
    Reference: 24 (25) 4184-4189

    paper

  • 271. Overall and disease specific survival of patients with screen-detected PC in the ERSPC, section Rotterdam

    De Vries SH, Postma R, Raaijmakers R, Roemeling S, Otto S, de Koning HJ, Schröder FH, 2007

    Journal: Eur Urol
    Reference: 51: 366-374

    paper

  • 270. Management and Survival of Screen-Detected Prostate Cancer Patients who Might Have Been Suitable for Active Surveillance

    Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schroder FH, 2006

    Journal: Eur Urol
    Reference: 50(3): 475-482

    paper

  • 269. The use of nomograms in the detection of prostate cancer.

    Roobol MJ., 2006

    Journal: Prostate
    Reference: 66: 1266-1267

    paper

← PreviousNext →